Long-acting somatostatin analogues decrease blood transfusion requirements in patients with refractory gastrointestinal bleeding associated with angiodysplasia

Summary Background Gastrointestinal angiodysplasias (GIADs) may be the cause of recurrent bleeding, despite endoscopic treatment. Aim To evaluate the effect of long‐acting somatostatin analogues on blood transfusion requirements, in patients with refractory bleeding due to GIADs. Methods Consecutive...

Full description

Saved in:
Bibliographic Details
Published in:Alimentary pharmacology & therapeutics 2012-09, Vol.36 (6), p.587-593
Main Authors: Bon, C., Aparicio, T., Vincent, M., Mavros, M., Bejou, B., Raynaud, J.-J., Zampeli, E., Airinei, G., Sautereau, D., Benamouzig, R., Michopoulos, S.
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Angiodysplasia - complications
Angiodysplasia - drug therapy
Biological and medical sciences
Blood Transfusion
Colonoscopy
Digestive system
Female
Gastroenterology. Liver. Pancreas. Abdomen
Gastrointestinal Hemorrhage - etiology
Gastrointestinal Hemorrhage - prevention & control
Gastroscopy
Hormones - therapeutic use
Humans
Male
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Randomized Controlled Trials as Topic
Somatostatin - analogs & derivatives
Somatostatin - therapeutic use
Time Factors
Tomography, X-Ray Computed
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Background Gastrointestinal angiodysplasias (GIADs) may be the cause of recurrent bleeding, despite endoscopic treatment. Aim To evaluate the effect of long‐acting somatostatin analogues on blood transfusion requirements, in patients with refractory bleeding due to GIADs. Methods Consecutive patients with recurrent bleeding from GIADs were enrolled. They received somatostatin analogue treatment for at least 6 months. The efficacy was evaluated in terms of blood transfusions, frequency of bleeding episodes and haemoglobin level during 6 months of treatment (Period During) compared to a 6‐months' period before treatment (Period Before). Results Fifteen patients were enrolled from 2007 to 2010. The median duration of somatostatin analogue treatment was 12 months (range: 6–36). The number of transfusions significantly decreased in Period During compared with Period Before [median number: 2 (0–14) vs. 10 (6–24); P 
ISSN:0269-2813
1365-2036
DOI:10.1111/apt.12000